ImmunityBio Shares Surge on Regulatory Pathway Clarity

ImmunityBio US45256X1037

ImmunityBio's stock experienced a dramatic rally on Tuesday, with shares climbing as much as 36% at one point. This powerful upward move was ignited by a critical development in the company's discussions with the U.S. Food and Drug Administration (FDA), providing a clear route forward for its supplemental drug application.

The surge stems directly from the outcome of a recent Type B End-of-Phase meeting. The discussions centered on ImmunityBio's supplemental Biologics License Application (sBLA) for its cancer therapy, ANKTIVA. The drug is being evaluated for treating non-muscle invasive bladder cancer (NMIBC) specifically in patients with papillary tumors.

A key takeaway for investors was the FDA's feedback. While the agency requested additional information for a resubmission, it explicitly did not mandate new clinical trials. This point is crucial, as conducting fresh studies would have consumed several years and required significant financial resources. The company stated it has already assembled the necessary data packages and plans to submit them within the next 30 days.

Reversing a Previous Setback

This news represents a substantial shift in momentum. In May 2025, the FDA had issued a Refusal to File letter for the original application, which heavily pressured the stock price at the time. The latest guidance alleviates concerns that the drug's development for this indication might be halted.

ANKTIVA is already approved for another form of bladder cancer (carcinoma in situ). Expanding its label to include papillary tumors would significantly broaden its market potential, given the limited alternatives to complete bladder removal for this patient group. Long-term data from the QUILT-3.032 study supports this potential, showing a specific survival rate of approximately 96% at 36 months. Commercially, the drug is gaining traction: preliminary 2025 figures indicate ANKTIVA revenue surged roughly 700% to $113 million.

The Path Forward

Attention now turns to the coming weeks. Following ImmunityBio's anticipated resubmission, the FDA must formally accept the application to restart the review clock. This action would establish a definitive timeline for a potential approval decision. Furthermore, the quarterly results expected in early March 2026 are likely to provide additional insight into the commercial progress of the company's existing business.